FDA Drug Shortages

Current and Resolved Drug Shortages and Discontinuations Reported to FDA

Start Over | Back to Previous Screen

Bumetanide Injection
Status: Currently in Shortage
»Date first posted: 12/13/2017
»Therapeutic Categories: Cardiovascular

Expand all

Hikma Pharmaceuticals USA, Inc. (formerly West-Ward) (Revised 01/13/2022)

Company Contact Information:
800-631-2174

Presentation Availability and Estimated Shortage Duration Related Information Shortage Reason (per FDASIA)
0.25 mg/mL, 4 mL vial (NDC 0641-6008-10) This presentation is temporarily on backorder. Additional lots are scheduled for manufacturing and will be available in the February 2022 timeframe. Product will be made available as it is released. Demand increase for the drug
0.25 mg/mL, 10 mL vial (NDC 0641-6007-10) This presentation is temporarily on backorder. Additional lots are scheduled for manufacturing and will be available in the February 2022 timeframe. Product will be made available as it is released. Demand increase for the drug

Hospira, Inc. (Revised 01/05/2022)

Company Contact Information:
844-646-4398

Presentation Availability and Estimated Shortage Duration Related Information Shortage Reason (per FDASIA)
1 mg/4 mL (0.25 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-1412-04) Limited Supply Available. Next Delivery: January 2022; Estimated Recovery: March 2022 Demand increase for the drug
2.5 mg/10 mL (0.25 mg/mL); Multiple Dose Glass Fliptop Vial (NDC 00409-1412-10) Limited Supply Available. Next Delivery: February 2022; Estimated Recovery: May 2022 Demand increase for the drug

Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English